Last mentioned: Mar 14, 2026
APOLLO Data Readout
Expected release of Phase 2 data which will support the traditional NDA filing.
FDA CRL Issued
Disc Medicine receives a Complete Response Letter for bitopertin's accelerated approval application.
Strategic Pivot
Company announces shift to traditional approval pathway for EPP indication.
Disc Medicine is shifting its regulatory strategy for bitopertin in erythropoietic protoporphyria (EPP) after receiving a Complete Response Letter from the FDA. The company will now pursue a traditional approval pathway, with critical Phase 2 APOLLO trial data expected in the fourth quarter of 2026.
This page surfaces every story mentioning APOLLO across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where APOLLO was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |